ClinicalTrials.gg
CompletedNCT07221981PRIORITY-COPDUpdated Oct 15, 2026

Study of Patient With Frequent COPD Exacerbations

An observational study in Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca. Completed at 30 sites in Russia. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by AstraZeneca · Observational

How we know

Updated Oct 15, 2026Now CompletedEnrollment updated+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
2,024
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
31st of 89
2,024 · median 976
Started
2024
with 16 others
Observational
90 of 284
7 open now
Registered
274th of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 31st largest by enrollment of the 89 observational ones that give a count, is one of 17 that started in 2024, is one of 90 observational ones, and was the 274th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

This Study is a multicenter, non-interventional, observational, ambispective (retrospective-prospective) study to evaluate clinical and demographic characteristics, approaches to therapy in outpatients with COPD and frequent exacerbations in the Russian Federation. Planned number of Study site is 35 outpatient centers with experience of treatment of COPD with frequency exacerbations in about 30 regions in Russia.

Read the detailed description

The study consists of a retrospective phase covering 52 weeks and a prospective phase of 24 weeks, involving 2000 patients across approximately 35 cites. Therefore, the aim of the study is to evaluate the clinical and demographic patients' characteristics based on retrospective part and COPD treatment patterns based on prospective part of patients with frequent exacerbations of COPD on dual therapy in the Russian Federation. The study results will be interpreted in the context of an open label, single arm study design. Due to the limited data available on the COPD population in Russia, the characterization of clinical and demographic characteristic of patients based on the retrospective component of the study will enhance the understanding of this patient group and the prospective aspect, which analyses therapeutic approaches, will help to assess physicians' adherence to current recommendations regarding therapy selection for COPD patients on dual therapy with frequent exacerbations.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • chronic obstructive pulmonary disease (COPD)
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

2000 adult patients with diagnosed moderate-to-severe COPD and ≥2 moderate or ≥1 severe exacerbations in previous 52 weeks despite two inhaled maintenance therapies (LABA/LAMA, ICS/LABA, ICS/LAMA) for at least 6 weeks prior to inclusion and are monitored and treated by pulmonologists or general practitioners

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years at the time of inclusion;
  2. Signed and dated written in accordance with ICH-GCP and local law prior to inclusion in the study;
  3. Patients with diagnosed moderate-to-severe (see comments below);
  4. ≥2 moderate or ≥1 severe COPD exacerbations in previous 52 weeks (see comments below);
  5. Patients have been receiving two inhaled maintenance therapies (LABA/LAMA, ICS/LABA, ICS/LAMA) for at least 6 weeks prior to inclusion.

Exclusion criteria

Exclusion Criteria:

  1. Current or previous treatment with triple combination (ICS/LABA/LAMA) within 52 weeks prior to inclusion;
  2. due to documented α-1 antitrypsin deficiency;
  3. A diagnosis of bronchiectasis, sarcoidosis, interstitial lung diseases, or idiopathic pulmonary fibrosis, exacerbation of bronchial asthma or any acute or chronic disease that, as deemed by Investigator, limits the ability of patients to participate in this study or could influence the interpretation of the results;
  4. The participation in any clinical study currently or within 52 weeks prior to inclusion.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
2,024 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. To describe the baseline Demographic data characterisics of outpatients with moderate and severe COPD.

    Demographic data 1. Mean age at the inclusion into the study, and age groups (\<50; 50-65, \>65 years); 2. Mean age at the primary COPD diagnosis; 3. Proportion of men and women; 4. Proportion of patients with each educational status (higher, secondary special, secondary general) at inclusion; 5. Proportion of patients from each residential region of Russia;

    Time frame: 52 weeks of retrospective data before visit 1

  2. To describe the baseline Negative lifestyle factors characterisics of outpatients with moderate and severe COPD.

    Negative lifestyle factors 6. Proportion of patients with negative lifestyle factors at inclusion (evaluated on Visit 1 based on patient's interview): a. Proportion of patients with history of smoking (former smoker)/current smokers - applicable for tobacco and e-cigarettes (vapes) smoking; d. Proportion of patients with overeating; e. Proportion of patient with physical inactivity.

    Time frame: 52 weeks of retrospective data before visit 1

  3. To describe the baseline Anthropometry data characterisics of outpatients with moderate and severe COPD.

    Anthropometry data 7. Mean body mass index (BMI) at inclusion (in previous 52 weeks (the most recent available value) or evaluated on Visit 1);

    Time frame: 52 weeks of retrospective data before visit 1

  4. To describe the baseline COPD drug treatment duration in previous 52 weeks of outpatients with moderate and severe COPD.

    9\. Proportion of patients receiving different classes of drugs for treatment of COPD during prior 52 weeks before inclusion. The following classes of drug or their combinations will be collected. The combinations may be prescribed as separate drugs or fixed combination (of ≥1 drug class in one medication): 1. SABA alone; 2. ICS alone 3. LABA alone 4. LAMA alone 5. LABA and LAMA 6. ICS and LABA 7. ICS and LAMA 8. LABA and LAMA plus: a) Macrolide antibiotics b) CS

    Time frame: 52 weeks of retrospective data before visit 1

  5. To describe the baseline Cardiovascular diseases of outpatients with moderate and severe COPD.

    Cardiovascular diseases 10. Proportion of patients with cardiovascular diseases (heart failure; ischaemic heart disease; myocardial infarction; arrhythmia; stroke; arterial hypertension; peripheral arterial disease; diabetes mellitus (type I, type II); chronic kidney disease (CKD); pulmonary hypertension) at inclusion (diagnosed in medical documentation ever or identified on the Visit 1 via a patient interview);

    Time frame: 52 weeks of retrospective data before visit 1

  6. To describe the baseline other comorbidities of outpatients with moderate and severe COPD.

    Other comorbidities 11. Proportion of patients with atrial fibrillation/flutter, ventricular arrhythmias, other arrhythmia (be calculated in patients with presence of arrhythmia before or on Visit 1); 18. Proportion of patients with different other comorbidities at inclusion (diagnosed in previous 52 weeks or on Visit 1).

    Time frame: 52 weeks of retrospective data before visit 1

  7. To describe the baseline Blood eosinophils count of outpatients with moderate and severe COPD.

    Blood eosinophils count 19. Mean blood eosinophils count (cells/μl) at inclusion (in previous 52 weeks (the most recent available value) or evaluated on Visit 1); 20. Proportion of patients with different levels of blood eosinophils count at inclusion (in previous 52 weeks (the most recent available value) or evaluated on Visit 1): 1. \<150 cells/μl; 2. ≥150 cells/μl; 3. ≥300 cells/μl.

    Time frame: 52 weeks of retrospective data before visit 1

  8. To describe the baseline mean smoking index .

    applicable for current/former tobacco smokers (pack-years)

    Time frame: 52 weeks of retrospective data before visit 1

  9. To describe the baseline mean duration of smoking

    applicable for current/former e-cigarettes (vapes) smokers (years);

    Time frame: 52 weeks of retrospective data before visit 1

  10. To describe the Proportion of patients with overweight

    determined as BMI ≥25 kg/m2 at inclusion (in previous 52 weeks (the most recent available value) or evaluated on Visit 1

    Time frame: 52 weeks of retrospective data before visit 1

  11. To describe the baseline dosages of COPD drug treatment in previous 52 weeks of outpatients with moderate and severe COPD.

    Proportion of patients receiving different classes of drugs for treatment of COPD. The following classes of drug or their combinations will be collected. The combinations may be prescribed as separate drugs or fixed combination (of ≥1 drug class in one medication): 1. dosage SABA alone ; 2. dosage ICS alone 3. dosage LABA alone 4. dosage LAMA alone 5. dosage LABA and LAMA 6. dosage ICS and LABA 7. dosage ICS and LAMA 8. LABA and LAMA plus: a) dosage Macrolide antibiotics b) dosage CS

    Time frame: 52 weeks of retrospective data before visit 1

  12. To describe the baseline proportion of patients with heart failure of outpatients with moderate and severe COPD.

    12\. Proportion of patients will be evaluated for each heart failure phenotype based on LVEF - HFrEF, HFmrEF, HFpEF (to be calculated in patients with presence of heart failure before or on Visit 1);

    Time frame: 52 weeks of retrospective data before visit 1

  13. To describe the baseline data of LVEF of patients with heart failure of outpatients with moderate and severe COPD.

    13\. Mean and median value of LVEF, % (to be calculated in patients with presence of heart failure before or on Visit 1 and available data on LVEF based on echocardiography);

    Time frame: 52 weeks of retrospective data before visit 1

  14. To describe the baseline proportion of patients with each CKD stage - C1, C2, C3a, C3b, C4, C5 of outpatients with moderate and severe COPD.

    14\. to be calculated in patients with presence of CKD before or on Visit 1.

    Time frame: 52 weeks of retrospective data before visit 1

  15. To describe the baseline mean office BP (SBP and DBP) measured at Visit 1 of outpatients with moderate and severe COPD.

    15\. this parameter evaluated in total population and in patients with presence of AH before or on Visit 1)

    Time frame: 52 weeks of retrospective data before visit 1

  16. To describe the baseline proportion of patients with AH by distribution by AH stage (I, II, III), AH degree (1st, 2nd, 3rd) and risk category at Visit 1 of outpatients with moderate and severe COPD.

    16\. to be evaluated in patients with presence of AH before or on Visit 1;

    Time frame: 52 weeks of retrospective data before visit 1

  17. To describe the baseline proportion of patients with various classes of medications used for treatment of CVD of outpatients with moderate and severe COPD.

    17\. to be evaluated in patients with at least one cardiovascular disease

    Time frame: 52 weeks of retrospective data before visit 1

Secondary outcomes

  1. To describe the proportion of patients receiving different classes of drugs for treatment of COPD between V1 and V2

    the proportion of patients with prescribed of the following classes of drug or their combinations. The combinations may be prescribed as separate drugs or fixed combination (of ≥1 drug class in one medication): 1. SABA alone 2. LABA alone 3. LAMA alone 4. ICS alone 5. ICS and LABA 6. ICS and LAMA 7. LABA and LAMA 8. ICS and LABA and LAMA (triple therapy)

    Time frame: 24 weeks after visit 1

  2. To describe Healthcare resource utilization during 24-week prospective study follow-up compared to baseline period

    7\. Proportion of patients with healthcare resource utilization events due to COPD during 52 weeks prior to inclusion (Visit 1): * Unscheduled outpatient visits; * Emergency department visits/emergency calls; * Hospitalizations. 8. Proportion of patients with healthcare resource utilization events due to COPD occurred from inclusion (Visit 1) to Visit 2: * Unscheduled outpatient visits; * Emergency department visits/emergency calls; * Hospitalizations.

    Time frame: 24 weeks after visit 1

  3. To describe changes of Mean forced expiratory volume during 24-week prospective study follow-up compared to baseline

    11\. Mean parameters of lung function at inclusion (Visit 1) and Visit 2: a. Mean forced expiratory volume in 1 second (pre- and post-FEV1); 12. change from baseline (Visit 1) to Visit 2: a. Pre- and post-bronchodilator FEV1;

    Time frame: 24 weeks after visit 1

  4. To describe Change in CAT score during 24-week prospective study follow-up compared to baseline

    13\. Mean baseline in the COPD Assessment Test (CAT) score at inclusion; 14. Mean change from baseline (at inclusion) to 24 weeks (Visit 2) in the CAT score;

    Time frame: 24 weeks after visit 1

  5. To describe Newly occurred cardiovascular diseases and other comorbidities during 24-week prospective study follow-up

    16\. The proportion of patients with newly occurred cardiovascular diseases (heart failure; ischaemic heart disease; myocardial infarction; arrhythmia; stroke; arterial hypertension; peripheral arterial disease; diabetes mellitus (type I, type II); chronic kidney disease (CKD); pulmonary hypertension; pulmonary embolism) during study follow-up, the analysis includes withdrawn patients; 17. The proportion of patients with newly occurred other (non-cardiovascular) comorbidities during study follow-up, the analysis includes withdrawn patients.

    Time frame: 24 weeks after visit 1

  6. To describe Blood eosinophils count during 24-week prospective study follow-up compared to baseline

    18\. Mean blood eosinophils count (cells/μl) on Visit 2; 19. Proportion of patients with different levels of blood eosinophils count on Visit 2: 1. \<150 cells/μl; 2. ≥150 cells/μl; 3. ≥300 cells/μl. 20. Mean change in blood eosinophils count (cells/μl) from baseline (Visit 1) to Visit 2.

    Time frame: 24 weeks after visit 1

  7. To describe COPD corticosteroid treatment during 24-week prospective study follow-up and change in therapy compared to baseline period

    3.Proportion of patients with CS prescribed during the study between Visit 1 and Visit 2 - overall and by type (CS intermittent; CS regularly);

    Time frame: 24 weeks after visit 1

  8. To describe Proportion of patients with macrolide antibiotics during 24-week prospective study follow-up and change in therapy compared to baseline period

    prescribed during the study between Visit 1 and Visit 2.

    Time frame: 24 weeks after visit 1

  9. To describe Proportion of patients with change of inhaled COPD therapy during the study during 24-week prospective study follow-up and change in therapy compared to baseline period

    between V1 and V2 compared to the baseline period (change in drug class: SABA alone, LABA alone, LAMA alone, ICS alone, open and fixed combination of ICS, LABA or LAMA, macrolide antibiotics; CS: intermittent or regularly; or starting of triple therapy with ICS/LABA/LAMA);

    Time frame: 24 weeks after visit 1

  10. To describe Mean duration of COPD-related hospitalizations during 52 weeks prior to inclusion

    will be described at Visit 1

    Time frame: 52 weeks of retrospective data before visit 1

  11. To describe Mean duration of COPD-related hospitalizations during 24-week prospective study follow-up compared to baseline period

    occurred from inclusion (Visit 1) to Visit 2.

    Time frame: 24 weeks after visit 1

  12. To describe changes of Mean forced vital capacity during 24-week prospective study follow-up compared to baseline

    * Mean forced vital capacity (FVC) at Visit 1 * Mean FVC change from baseline (Visit 1) to Visit 2

    Time frame: 24 weeks after visit 1

  13. To describe changes of Mean post-bronchodilator FEV1/FVC ratio during 24-week prospective study follow-up compared to baseline

    * at Visit 1 * change from baseline (Visit 1) to Visit 2

    Time frame: 24 weeks after visit 1

  14. To describe Percent of responders using the CAT who achieved MCID (minimal clinically important difference) during 24-week prospective study follow-up compared to baseline

    Determined as 2 or more points after 24 weeks from baseline;

    Time frame: 24 weeks after visit 1

  15. To describe Mean CS daily dose (mg/day in prednisolone equivalent) during the study between Visit 1 and Visit 2 during 24-week prospective study follow-up and change in therapy compared to baseline period

    evaluated in patients with CS prescribed during the study

    Time frame: 24 weeks after visit 1

  16. To describe Proportion of patients with CS using for COPD exacerbations treatment during the study

    between Visit 1 and Visit 2 during 24-week prospective study follow-up and change in therapy dose compared to baseline period

    Time frame: 24 weeks after visit 1

  17. To describe proportion of patients with COPD-related disability present at the inclusion

    for each disability group (I, II, III)

    Time frame: at visit 1

  18. To describe proportion of patients with COPD-related disability changing during study follow-up

    by disability group (I, II, III) assigned at the changing (to be evaluated in patients with disability present at Visit 1)

    Time frame: 24 weeks after visit 1

  19. To describe proportion of patients with COPD-related disability newly established during study follow-up

    by disability group (I, II, III) assigned at the establishing (to be evaluated in patients with disability absent at Visit 1).

    Time frame: 24 weeks after visit 1

  20. To describe proportion of patients with atrial fibrillation/flutter, ventricular arrhythmias, other arrhythmia

    be calculated in patients with arrhythmia diagnosed during study follow-up

    Time frame: 24 weeks after visit 1

  21. To describe proportion of patients with each heart failure phenotype based on LVEF - HFrEF, HFmrEF, HFpEF

    to be calculated in patients with heart failure diagnosed during study follow-up

    Time frame: 24 weeks after visit 1

  22. To describe Mean and median value of LVEF, %

    to be calculated in patients with heart failure diagnosed during study follow-up and available data on LVEF based on echocardiography;

    Time frame: 24 weeks after visit 1

  23. To describe proportion of patients with decompensation of previously diagnosed heart failure

    to be calculated in patients with heart failure diagnosed before or at Visit 1;

    Time frame: 24 weeks after visit 1

  24. To describe proportion of patients with each CKD stage - C1, C2, C3a, C3b, C4, C5

    to be calculated in patients with CKD diagnosed during study follow-up;

    Time frame: 24 weeks after visit 1

  25. To describe proportion of patients with each type of stroke occurred during the study follow-up - ischemic, hemorrhagic

    to be calculated in patients with stroke occurred during study follow-up;

    Time frame: 24 weeks after visit 1

  26. To describe mean office BP (SBP and DBP) measured at Visit 2

    this parameter evaluated in total population and in patients with AH diagnosis established at any time;

    Time frame: 24 weeks after visit 1

  27. To describe proportion of patients with AH by distribution by AH stage (I, II, III), AH degree (1st, 2nd, 3rd) and risk category at Visit 2

    to be evaluated in patients with AH diagnosis established at any time;

    Time frame: 24 weeks after visit 1

  28. To describe proportion of patients with various classes of medications used for treatment of CVD

    to be evaluated in patients with at least one cardiovascular disease from listed above;

    Time frame: 24 weeks after visit 1

07

Study locations

30 sites
  • Research Site
    Barnaul, Russia
  • Research Site
    Chelyabinsk, Russia
  • Research Site
    Ivanovo, Russia
  • Research Site
    Izhevsk, Russia
  • Research Site
    Kazan', Russia
  • Research Site
    Kemerovo, Russia
  • Research Site
    Krasnodar, Russia
  • Research Site
    Krasnoyarsk, Russia
  • Research Site
    Moscow, Russia
  • Research Site
    Nizhny Novgorod, Russia
  • Research Site
    Novokuznetsk, Russia
  • Research Site
    Novosibirsk, Russia
  • Research Site
    Omsk, Russia
  • Research Site
    Orenburg, Russia
  • Research Site
    Perm, Russia
  • Research Site
    Petrozavodsk, Russia
  • Research Site
    Rostov-on-Don, Russia
  • Research Site
    Ryazan, Russia
  • Research Site
    Saint Petersburg, Russia
  • Research Site
    Samara, Russia
  • Research Site
    Stavropol, Russia
  • Research Site
    Tomsk, Russia
  • Research Site
    Tyumen, Russia
  • Research Site
    Ufa, Russia
  • Research Site
    Ulan-Ude, Russia
  • Research Site
    Vladivostok, Russia
  • Research Site
    Volgograd, Russia
  • Research Site
    Voronezh, Russia
  • Research Site
    Yakutsk, Russia
  • Research Site
    Yekaterinburg, Russia
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Jun 2026, 18 months.

Of 120 industry-sponsored observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 18 months is below that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
Oct 29, 2025
StartActual
Dec 16, 2024
Primary completionActual
Jun 22, 2026
CompletionActual
Jun 22, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 6, 2026
Sites
30 sites added, 6 sites removed
Show 30 added (30 Russia)
  • Research Site · Barnaul, Russia
  • Research Site · Chelyabinsk, Russia
  • Research Site · Ivanovo, Russia
  • Research Site · Izhevsk, Russia
  • Research Site · Kazan', Russia
  • Research Site · Kemerovo, Russia
  • Research Site · Krasnodar, Russia
  • Research Site · Krasnoyarsk, Russia
  • Research Site · Moscow, Russia
  • Research Site · Nizhny Novgorod, Russia
  • Research Site · Novokuznetsk, Russia
  • Research Site · Novosibirsk, Russia
  • Research Site · Omsk, Russia
  • Research Site · Orenburg, Russia
  • Research Site · Perm, Russia
  • Research Site · Petrozavodsk, Russia
  • Research Site · Rostov-on-Don, Russia
  • Research Site · Ryazan, Russia
  • Research Site · Saint Petersburg, Russia
  • Research Site · Samara, Russia
  • Research Site · Stavropol, Russia
  • Research Site · Tomsk, Russia
  • Research Site · Tyumen, Russia
  • Research Site · Ufa, Russia
  • Research Site · Ulan-Ude, Russia
  • Research Site · Vladivostok, Russia
  • Research Site · Volgograd, Russia
  • Research Site · Voronezh, Russia
  • Research Site · Yakutsk, Russia
  • Research Site · Yekaterinburg, Russia
Show 6 removed
  • Research site · Ivanovo, Russia
  • Research site · Moscow, Russia
  • Research site "OOO Energy of health" · Saint Petersburg, Russia
  • Research site · Saint Petersburg, Russia
  • Research site · Voronezh, Russia
  • Research site · Yekaterinburg, Russia
Oct 15, 2026
Primary completion
Jun 30, 2026→Jun 22, 2026 (actual)
Oct 6, 2026
Study completion
Jun 30, 2026→Jun 22, 2026 (actual)
Oct 6, 2026
Enrollment
2038→2024
Oct 15, 2026
Show all 2 updates
  1. Oct 15, 2026
    30 sites added, 6 sites removed
    Show 30 added (30 Russia)
    • Research Site · Barnaul, Russia
    • Research Site · Chelyabinsk, Russia
    • Research Site · Ivanovo, Russia
    • Research Site · Izhevsk, Russia
    • Research Site · Kazan', Russia
    • Research Site · Kemerovo, Russia
    • Research Site · Krasnodar, Russia
    • Research Site · Krasnoyarsk, Russia
    • Research Site · Moscow, Russia
    • Research Site · Nizhny Novgorod, Russia
    • Research Site · Novokuznetsk, Russia
    • Research Site · Novosibirsk, Russia
    • Research Site · Omsk, Russia
    • Research Site · Orenburg, Russia
    • Research Site · Perm, Russia
    • Research Site · Petrozavodsk, Russia
    • Research Site · Rostov-on-Don, Russia
    • Research Site · Ryazan, Russia
    • Research Site · Saint Petersburg, Russia
    • Research Site · Samara, Russia
    • Research Site · Stavropol, Russia
    • Research Site · Tomsk, Russia
    • Research Site · Tyumen, Russia
    • Research Site · Ufa, Russia
    • Research Site · Ulan-Ude, Russia
    • Research Site · Vladivostok, Russia
    • Research Site · Volgograd, Russia
    • Research Site · Voronezh, Russia
    • Research Site · Yakutsk, Russia
    • Research Site · Yekaterinburg, Russia
    Show 6 removed
    • Research site · Ivanovo, Russia
    • Research site · Moscow, Russia
    • Research site "OOO Energy of health" · Saint Petersburg, Russia
    • Research site · Saint Petersburg, Russia
    • Research site · Voronezh, Russia
    • Research site · Yekaterinburg, Russia
    Enrollment 2038→2024
    + 1 other change: verification date
  2. Oct 6, 2026
    Active, not recruiting→Completed
    Primary completion Jun 30, 2026→Jun 22, 2026 (now actual)
    Study completion Jun 30, 2026→Jun 22, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07221981
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 29, 2025
Start date
Dec 16, 2024
Primary completion
Jun 22, 2026
Completion
Jun 22, 2026
Last update
Oct 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion